Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors and were among the first solid tumor types for which such a novel treatment (in this case imatinib) became available. The ...

For patients with gastrointestinal stromal tumors with liver metastases, treatment with surgery and chemotherapy has been found to have survival benefits. Among patients with gastrointestinal stromal ...

Management trends and outcomes of appendiceal cancers: A National Cancer Database study. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not ...

The British pharma giant plans to shell out $1 billion upfront to buy the drug developer working on a lead treatment for gastrointestinal stromal tumors. As the first morning of the J.P. Morgan ...

Bezuclastinib plus sunitinib showed favorable safety and efficacy in GIST, outperforming sunitinib alone in phase 3 Peak ...

Treatment with bezuclastinib plus Sutent led to safe and efficacious outcomes versus Sutent treatment alone in gastrointestinal stromal tumors.

which is a highly selective KIT Tyrosine Kinase Inhibitor being developed as a first- and second-line therapy for treating gastrointestinal stromal tumors or GIST. The consideration includes $1 ...

[25] In view of these data, imatinib has become the first-line treatment for patients presenting with advanced GIST. Since the 800 mg dose causes more pronounced toxic effects but equivalent ...